EghtesadOnline: Mylan NV on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, which has come under intense scrutiny after a series of drastic price increases.

EghtesadOnline: U.S. lawmakers on Wednesday blasted Mylan NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U.S. drug costs.

EghtesadOnline: Teva Pharmaceutical Industries Ltd said Friday it aims to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's EpiPen device for treating severe allergic reactions, a move that would challenge the branded product's overwhelming market dominance.

EghtesadOnline: Democrat Elizabeth Warren and 19 other U.S. senators voiced concern to the chief executive of Mylan NV about the high cost of its EpiPen on Tuesday, calling the device used in the case of life-threatening allergies "exorbitantly expensive."